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Abstract 
 
 
Objectives: Evaluate the use of probiotic as additional therapy in the treatment of 
children and adolescents with asthma in Belo Horizonte, MG-Brazil. Methods: A pilot 
longitudinal, experimental and non-randomized study with 30 patients from six to 17 
years old from Belo Horizonte. In the basal appointment, all patients received 
beclomethasone and one group received a probiotic containing Lactobacillus reuteri 
(n=14). The patients were reassessed after 60 days at least, being submitted to the 
Asthma Control Test, spirometry and report the symptoms associated to asthma.  
Results: It was observed predominance of male sex (56.7%) and mean age of 10.6 
years. The groups using probiotic did not differ regarding sex, age or atopy. In the 
longitudinal evaluation, it was observed an increase of the Asthma Control Test in 
probiotic group, as well as the reduction of the number of symptoms. There was an 
increase in the peak expiratory flow among those who used or not probiotic. 
Conclusions: This pilot study raise the hypothesis that the administration of probiotic 
as a supplementary therapy for the treatment of children and adolescents with 
DVWKPDVHHPVWRKDYH LPSURYHGWKHSDWLHQWV¶FOLQLFDOFRQGLWLRQ)XUWKHUVWXGLHVDUH
needed to confirm the efficacy of probiotics in the asthma treatment.  
 
 
 
Key words: Respiratory Hypersensitivity, Asthma, Public health, Respiratory 
Function Tests, Probiotics. 
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Introduction 
 
Asthma is an airway inflammation that leads to a variable obstruction of 
intrapulmonary airflow, leading to recurrent episodes of breathlessness, wheeze, 
chest tightness and coughing (1,2). Asthma is the most common chronic disease in 
childhood (3), and it is estimated that up to 14% of children and 8.6% of adults 
worldwide have symptoms of this pathology (4). There is low mortality associated 
with asthma (3); however, it has a considerable financial and social cost, as well as 
being a prevalent cause of disability (5). 
According to the guidelines of the Global Initiative for Asthma (2), the primary 
goal of asthma treatment is to obtain an optimal control of the disease, with minimum 
or absence of day and night symptoms, no limitation to physical activity, minimum 
need for medication for the relief of symptoms, normal pulmonary function or with a 
value close to normal, and the absence of exacerbations. All of this must be obtained 
with the use the lowest possible extent of medication, especially corticosteroids, 
according to a phased plan that takes into consideration the control of the disease, its 
severity and future risks (1,6). The use of probiotics arises as a possibility of 
additional therapy for treatment.  
Probiotics are defined as "live microorganisms that when administered in 
DGHTXDWH DPRXQWV FRQIHU EHQHILWV WR WKH KRVW¶V KHDOWK 7,8). The use of these 
RUJDQLVPV FRXOG SURYLGH EHQHILWV WR SDWLHQW¶V LPPXQH V\VWHP OHDGLQJ to a better 
control of the disease with reduction of symptoms and an improvement in lung 
function of these patients. Besides, others action mechanisms of the probiotics 
includes the increase of epithelial barrier, adhesion to intestinal mucosa, inhibition of 
pathogen adhesion, exclusion of pathogenic microorganisms by competition and anti-
microorganism substances production (7-9). 
Several studies have investigated possible benefits of probiotics for prevention 
and/or treatment of asthma. A pilot study investigated the effects of probiotics in 
asthmatic children, conducted by Stockert et al. (10), found an improvement in lung 
IXQFWLRQSHDNRIH[SLUDWRU\IORZ>3()@EXWQRLPSDFWRQSDWLHQWV¶TXDOLW\RIOLIHDQG
use of asthma medications. Furthermore, Chen et al. (11) observed improvement in 
symptoms, lung function and immunological parameters in children who received 
probiotics. Liu et al. (12) suggests probiotic could enhance therapeutic effect of 
allergen specific immunotherapy in asthmatics. In studies performed in rats with 
allergic inflammation of the airways receiving injections of Lactobacillus reuteri, 
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Forsythe et al. (13) and Karimi et al. (14) observed a mitigation of inflammation and 
airway hyperresponsiveness in the group of animals that received the probiotic. 
However, there are some studies in which there was no evidence of beneficial effects 
of probiotics on asthmatics or allergics (15-20). These include the study by 
Giovannini et al. (15) in Italy with children suffering from allergic asthma and/or 
rhinitis from two to five years. The authors found that the administration of probiotics 
did not promote improvements among patients with asthma in relation to time free 
from symptoms or the number of episodes of the disease.  
Rose et al. (16) examining the impact of Lactobacillus rhamnosus GG ATCC 
53103 in children aged 6 to 24 months with wheezing and family history of atopic 
diseases (in first-degree relatives) for six months also found no association between 
inhalation need and number of days free from symptoms among children who 
received or did not receive the probiotic. 
Given the current controversy about the use of probiotic in children with 
asthma, the aim of this pilot study was to evaluate the effect of the including probiotic 
as a supplementary therapy to inhaled corticosteroids (ICS), dipropionate 
beclomethasone, in the treatment of children and adolescents with asthma in a 
Secondary Referral Unit (SRU) of Belo Horizonte, MG-Brazil. In particular, it 
investigated the effect of Lactobacillus reuteri since there are no previous Brazilian 
studies investigating its possible use. 
 
Methods 
 
Study design  
 This is a longitudinal, quasi-experimental pilot study with control group 
involving asthmatic children and adolescents aged between 6 and 17 years old 
treated in a SRU in Belo Horizonte between January 2015 and December 2015. 
 
Study participants  
Children and adolescents who were newly diagnosed with mild to moderate 
asthma (2) not previously prescribed an ICS or short-acting beta2-agonist (SABA) 
were included. Patients suffering from other respiratory disorders such as 
bronchiolitis obliterans, interstitial pneumonia, sickle-cell disease, cystic fibrosis, 
sequels due to complicated pneumonia, tuberculosis or primary ciliary dyskinesia 
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were excluded. In addition, smokers, patients with cognitive impairment in the first 
attempt after initiation of the study were precluded. 
During the baseline appointment, all children received the medicine and the 
prescription of conventional therapy beclomethasone (Clenil®  ȝJVKRW - 
/DERUDWRU\ &KLHVL %UD]LO DW D GRVH RI  ȝJ WZLFH GDLO\ KRXUV ȝJGD\ DQG
had the term of consent signed. The Aerolin® (sulphate of salbutamol 120.5 mcg, 
QRUIOXUDQRT6S/DERUDWRU\*VN%UD]LODWDGRVHRIȝJZDVSUHVFULEHG in case 
of exacerbations. One group received the probiotic ProVance® (Laboratory Aché, 
Brazil) composed of 108 colony-forming units of Lactobacillus reuteri DSM 17938, at 
a dose of one capsule/day (8) and the other received a placebo (or no additional 
treatment for asthma). The allocation was performed in accordance with the final digit 
of the patient record, and the odd number ones received the probiotic. 
 
Study outcomes  
To evaluate the probiotics effects, the patients were reassessed in a minimum 
period of 60 days after the initiation of treatment. The outcomes of interest were the 
assessment of asthma control, pulmonary function and the frequency of main asthma 
symptoms.  
 At the two appointments, patients completed the asthma control test (ACT) 
(21), a spirometry with bronchodilator test and an assessment of the following 
symptoms: cough, wheezing, tiredness, chest pains, night-time symptoms (all 
symptoms cited before at night), limitations in physical activities and any school 
absenteeism. A skin allergy test was performed only in the first baseline appointment 
to identify atopic patients. A list of potential advent effects of probiotics were given to 
SDWLHQW¶V DQG WKHLU FDUHJLYHUV LQ RUGHU WR EH REVHUYHG WKHLU RFFXUUHQFH GXULQJ WKH
treatment. 
 
ACT 
Nathan et al. (22) developed the Asthma Control Test to monitor 
responsiveness to clinical changes. It had been validated with internal consistency. 
The questionnaire has been validated for use in Brazil (21) in order to measure the 
ability to discriminate controlled from uncontrolled asthma, as well as the 
reproducibility and responsiveness of the questionnaire among Brazilian patients. 
ACT has five questions and assesses the frequency of shortness of breath and 
general asthma symptoms, use of rescue medications, the effect of asthma on daily 
7 
 
functioning, and overall self-assessment of asthma control in the last four weeks. 
Scores range from 5 (poor control of asthma) to 25 (complete control of asthma) and 
high scores reflect greater asthma control. Asthma is classified as controlled if the 
score is greater than 19. 
 
Spirometry 
 The spirometry test was performed using the VMI ATS (Clement Clarke, 
EC0120, United Kingdom) in standing patients, positioning the mouthpiece of a 
disposable spirometer in the mouth and blocking the nostrils with a nose clip. The 
test was administered by an accredited technician. The device was calibrated daily 
prior of testing. The patients underwent a maximum inspiration followed by a 
maximum forced exhalation. This procedure was repeated three times before and 15-
20 minutes after inhalation of a fast acting bronchodilator  spray - Aerolin® (sulphate 
of salbutamol 120.5 mcg, norfluranoq.S.p. Laboratory Gsk, Brazil). Measurements 
were performed of forced vital capacity (FVC), forced expiratory volume in one 
second (FEV1), PEF and the Tiffeneau index (FEV1/FVC). The predicted values were 
obtained from the equations of Koopman et al. (23).  
 
Evaluation of adverse effects 
 The caregivers were questioned about the occurrence of the following 
symptoms that could indicate any adverse reactions of probiotics. These included 
diarrhea, vomiting, nausea, abdominal discomfort, burning sensation in the stomach 
DQGRUDEDGWDVWHLQWKHLUPRXWKQRWUHODWHGWRWKHSDWLHQWV¶IRRGKDELWV 
 
Data analysis 
 This is a pilot study designed for an exploratory analysis and as a proof of 
concept study about the inclusion of probiotics as supplementary treatment of 
asthmatics. There was no calculation of sample size. The findings would be used to 
calculate the sample size for a larger study. 
 The categorical variables were presented as frequencies, and the numerical 
as mean ± standard deviation (sd), in the case of normality (assessed via the 
Shapiro-Wilk test), or median ± inter-quartile range (IQR), in the case of non-normal 
distribution. To evaluate the association among categorical variables the Fisher exact 
test was used for independent samples and McNemar chi-square test for longitudinal 
analysis. For the comparison of numerical variables between two groups, Student-t 
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and Wilcoxon tests have been adopted in their versions for independent samples and 
paired ones. The analyzes were performed using the free program R version 3.3.2. 
The interpretation of p-values was only descriptive, at 5% of significance level. 
 
 
Ethical approval 
This study was approved by the Research Ethics Committee of the University 
Hospital São José/University Medical Sciences - MG under the number CAAE 
36416714.4.0000.5134. 
 
Results 
 
 During the study, 37 patients met the inclusion criteria, four of them were 
excluded due to being present at only one appointment (one probiotic group) and 
three for having been at the second appointment with less than 60 days in between 
(one in the probiotic group). The sample was composed of 30 children and 
adolescents, 14 received the probiotic. There was a predominance of males (56.7%), 
the mean age was 10.6 ± 2.5 years and the mean body mass index (BMI) was 18.8 ± 
3 kg/m2. The median time between the baseline and the second appointment was 63 
± 7 days, 63.3% of the patients had already been hospitalized, 80% had already 
sought emergency care and 70% were classified as atopic subjects in allergy tests at 
baseline. Among the patients using probiotics, 50% were boys, the mean age was 11 
± 2.5 years, the mean BMI 19.9 ± 3.4 kg/m2, 42.9% had already been hospitalized, 
64.3% had already been in emergency care, 71.4% were atopic. There were no 
significant differences in patient characteristics between the control and intervention 
group (Table 1). 
 In the longitudinal evaluation, there was a significant increase in the ACT 
score among patients who used probiotics, (difference mean ± sd 3.85 ± 6.7, 
p=0.049) (Figure 1) and a significant reduction in the number of symptoms 
(difference mean ± sd -2.64 ± 3.48, p=0.023). In addition, there was a reduction in 
the number of patients who reported wheezing (78.6% to 21.4%, p=0.046). There 
were no significative differences in control group (Table 2). 
Regarding the parameters measured by pre-bronchodilator spirometry, it was 
an increase of PEF among patients who did not (difference mean ± sd 12.47 ± 
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12.33%, p=0.005) and who consumed the probiotic (difference mean ± sd 17.89 ± 
17.54, p=0.005) (Table 3).  
 The occurrences of the signs of possible adverse effects did not differ 
between patients who received or not the probiotic. 
 
Discussion 
 
The groups were similar and comparable. There was no significant difference 
between the groups of patients who used or not the Lactobacillus reuteri. In the 
group who received the supplement, an increase in ACT score and a decrease in the 
number of symptoms, in particular the occurrence of wheezing, was seen with no 
significant changes in the control group. The spirometry results were common to the 
two groups (longitudinal increase of pre- bronchodilator PFE), which implies that 
SURELRWLFVKDGQRLPSDFWRQSDWLHQWV¶VSLURPHWU\WHVWV7KHSRVVLEOHDGYHUVHHIIHFWV
evaluated were not associated to the use of the supplement. 
The longitudinal increase of PEF pre-bronchodilator indicates a possible 
improvement in relation to the obstruction of the lower airways, by decreasing the 
bronchial hyperresponsiveness in all patients. These results may have been 
influenced by the insertion of the standard treatment (beclomethasone in patients 
who were not previous users of both ICS and SABA), by the guidelines about the 
allergic markers and also by climatic changes between the evaluations. The increase 
in PEF in the sample, for example, was expected with the insertion of the regular 
treatment by ICS for a period of two months (2). Another possible explanation would 
be a better performance of patients in the second test due to training they had when 
they performed it previously. This is notable in PEF, as this is a functional parameter 
effort-dependent (24). FEV1 is the most important parameter of follow-up of patients 
with asthma, since its fall increases the risk of exacerbations, regardless of the 
presentation of the symptoms (25). 
The findings of this pilot study suggest that the use of probiotics may have 
promoted an attenuation of clinical symptoms, since the ACT evaluates in four of five 
questions aspects related to the symptoms. However, this needs to be evaluated 
further before any definitive statements can be made due to the small sample size. 
These findings are similar to those of Chen et al. (11) who showed a decrease in 
asthma/allergic rhinitis symptoms, and improvements in FEV1, FVC and FEV1/FVC 
measured in the spirometry and PEF measured daily for patients who received 
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probiotic. The authors also reported significant reduction of immunological 
parameters measured in peripheral blood mononuclear cells (TNF-Į ,)1-Ȗ ,/-12 
and IL-13). However, we did not see an improvement in lung function in the probiotic 
group in our study. This difference could be due to variations in the method used to 
measure lung function.  
In addition, Stockert et al. (10) found a reduction of the variation of PEF in 
patients who used a probiotic, however, not differences were identified in the 
assessment of FEV1, quality of life and use of extra medications. The findings from 
Stockert et al. (10) resembles the present study with respect to improvements in lung 
function, evaluated, in this case by daily variation of PEF measured with a portable 
measuring instrument. The differences observed in the results between the two 
studies could potentially be explained by the use of different strains of probiotics 
promoting different benefits to the host (8).  
Prescott and Bjorksten (26) reported that the effects of probiotics on allergic 
diseases can be influenced by factors such as genetic differences in microbial 
response, microbial composition, individual microbiota, diet, allergic predisposition 
and use of antibiotics which could also account for the different results seen. 
However, in our study we did not find association between the probiotics effect and 
allergic profile. 
As limitations, we have the quasi-experimental characteristics (non-
randomization and not blinding of participants and researchers). The use of 
.RRSPDQ¶V HTXDWLRQV IRU WKH SUHGLcted values of spirometry parameters has been 
GHULYHGIURPDVDPSOHWKDWLQFOXGHVWKHFKLOGUHQDQGDGROHVFHQWV¶DJHUDQJH7KHUH
are no national equations recently published derived from a sample of Brazilian 
children and adolescents up to the time of initiation of this study. The ACT was 
developed for adolescents of at least 12 years old. The application of the ACT to 
sample of patients younger than 12 years old in this study is mitigated due to the fact 
that children below 12 years were helped by their caregivers in completing the 
questionnaire.  
The results of this pilot study suggests a trend towards improvement of the 
clinical profile of asthmatic patients who had the Lactobacillus reuteri as a 
supplementary therapy.  
This is one of the first investigations on the efficacy of probiotics carried out 
with Brazilian children and adolescents suffering from asthma. However, given 
conflicting results in the literature, the known variability on effects of probiotics for 
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each strain, and currently little knowledge about the mechanism of the potential 
benefits of probiotics in patients with asthma, we believe more studies are necessary, 
especially randomized controlled clinical trials and prospective cohort studies, to 
gather more evidence and knowledge about the possible potential benefits of 
probiotics to asthmatic patients before their routine use in children can be advocated.  
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Legend of Figure 
Figure 1. Asthma Control Test Scores for probiotic use 
 
Tables 
Table 1. Clinical and sociodemographic characteristics of the asthmatic children and 
adolescents at the baseline. Belo Horizonte, 2015. 
Variables 
Controls 
(n=16) 
Probiotics 
(n=14) 
P-value 
    
Male gender 10 (62.5%) 7 (50%) 0.713F 
    
Follow-up time (days) 63 ± 14 63.5 ± 7 0.836 W 
    
Age (years) 10.2 ± 2.5 11 ± 2.5 0.383T 
    
Body mass index (kg/m2) 17.8 ± 2.2 19.9 ± 3.4 0.059T 
15 
 
    
Hospitalization 13 (81.3%) 6 (42.9%) 0.057F 
    
Emergency care 15 (93.8%) 9 (64.3%) 0.072F 
    
Atopic allergy test 11 (68.8%) 10 (71.4%) 1.000F 
    
P-values refers to: F Fisher exact, T Student-t and W Wilcoxon Mann-Whitney for independent samples. 
 
 
 
 
 
 
 
 
Table 2. Symptoms history of the asthmatic children and adolescents according to 
the use of probiotic. Belo Horizonte, 2015. 
Variables Measures 
Controls 
(n=16) 
Probiotics 
(n=14) 
P-value 
     
Number of 
symptoms 
Baseline 2 ± 5.5 4 ± 3 0.054W 
2nd consultation 1 ± 2.5 1 ± 3 0.669W 
P-value 0.251Wp 0.023Wp  
     
Cough 
Baseline 7 (43.8%) 13 (92.9%) 0.007F 
2nd consultation 6 (37.5%) 7 (50%) 0.713F 
P-value 1.000Mc -  
     
Wheezing 
Baseline 5 (31.2%) 11 (78.6%) 0.014F 
2nd consultation 1 (6.2%) 3 (21.4%) 0.316F 
P-value 0.371Mc 0.046Mc  
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Tiredness 
Baseline 5 (31.2%) 10 (71.4%) 0.066F 
2nd consultation 5 (31.2%) 4 (28.6%) 1.000F 
P-value 1.000Mc 0.077Mc  
     
Chest pain 
Baseline 4 (25%) 5 (35.7%) 0.694F 
2nd consultation - 2 (14.3%) 0.209F 
P-value - 0.371Mc  
     
Nighttime 
symptoms 
Baseline 10 (62.5%) 10 (71.4%) 0.709F 
2nd consultation 4 (25%) 5 (35.7%) 0.694F 
P-value 0.131Mc 0.131Mc  
     
Limitation of 
physical 
activities 
Baseline 4 (25%) 5 (35.7%) 0.694F 
2nd consultation 2 (12.5%) 4 (28.6%) 0.378F 
P-value 1.000Mc 1.000Mc  
     
Absent from 
school 
Baseline 7 (43.8%) 7 (50%) 1.000F 
2nd consultation 4 (25%) 3 (21.4%) 1.000 F 
P-value 0.617Mc 0.221Mc  
     
P-values refers to: F Fisher exact, Mc McNemar Chi-Square test, Wp Wilcoxon for paired samples and W  
Wilcoxon Mann-Whitney for independent samples 
 
 
 
 
Table 3. Pre-salbutamol spirometry parameters, as percentage of predicted values, 
of the asthmatic children and adolescents according to the use of probiotic. Belo 
Horizonte, 2015 
Variables 
Controls 
(n=16) 
Probiotics 
(n=14) 
P-value 
    
FEV1(L)    
Baseline 77.6 ± 16.9 79.4 ± 14 0.667W 
2nd consultation 81.5 ± 8.4 85.5 ± 8.1 0.242W 
P-value 0.301Wp 0.147Wp  
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FVC (L)    
Baseline 54.1 ± 15.3 61.5 ± 26.8 0.381T 
2nd consultation 57.4 ± 20.5 68.1 ± 25.7 0.254T 
P-value 0.947Tp 0.396Tp  
    
FEV1/FVC (%)    
Baseline 104 ± 15.1 97 ± 21.6 0.910W 
2nd consultation 106.8 ± 10.3 106.9 ± 14.1 0.920W 
P-value 0.476Wp 0.306Wp  
    
PEF (L/min)    
Baseline 75.5 ± 19.5 74.9 ± 17.3 0.928T 
2nd consultation 85.7 ± 20.2 86.8 ± 16.5 0.871T 
P-value 0.005Tp 0.005Tp  
    
P-values refers to the tests: F Fisher exact, T Student-t e W Wilcoxon Mann-Whitney for independent 
samples,Tp Student-t e WpWilcoxon for paired samples 
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity, PEF = peak expiratory 
flow 
 
 
 
 
